Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
Saved in:
| Title: | Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. |
|---|---|
| Authors: | Lee JV; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Housley F; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Yau C; Cancer and Developmental Therapeutics Program, Buck Institute for Research on Aging, Novato, California, USA.; Departments of Pathology and Laboratory Medicine, University of California, San Francisco, California, USA., Nakagawa R; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Winkler J; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Anttila JM; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki, Helsinki, Finland., Munne PM; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki, Helsinki, Finland., Savelius M; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki, Helsinki, Finland., Houlahan KE; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA., Van de Mark D; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Hemmati G; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Hernandez GA; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Zhang Y; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Samson S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.; Breast Science Advocacy Core, UCSF Breast Oncology Program, San Francisco, California, USA., Baas C; Alamo Breast Cancer Foundation, San Antonio, Texas, USA., Kok M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Esserman LJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.; Department of Surgery, University of California, San Francisco, California, USA.; Department of Radiology, University of California, San Francisco, California, USA., van 't Veer LJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.; Departments of Pathology and Laboratory Medicine, University of California, San Francisco, California, USA., Rugo HS; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.; Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, California, USA., Curtis C; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California, USA.; Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.; Department of Genetics, Stanford University School of Medicine, Stanford, California, USA., Klefström J; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Translational Cancer Medicine, Medical Faculty, University of Helsinki, Helsinki, Finland., Matloubian M; Department of Medicine, Division of Rheumatology and Rosalind Russell/Ephraim P Engleman Rheumatology Research Center, University of California, San Francisco, California, USA. mehrdad.matloubian@ucsf.edu., Goga A; Department of Cell and Tissue Biology, University of California, San Francisco, California, USA. andrei.goga@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA. andrei.goga@ucsf.edu.; Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, California, USA. andrei.goga@ucsf.edu. |
| Source: | Nature communications [Nat Commun] 2022 Nov 21; Vol. 13 (1), pp. 7140. Date of Electronic Publication: 2022 Nov 21. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-022-34570-5 |
